Manhattan Scientifics Inc. announced today that it will host a conference call for MHTX investors at 12:00 pm Eastern Time on Friday, June 16, 2017 to provide an update and briefing on the pending Imagion Biosystems IPO (IBX). There will not be a Q&A Session and participants will be restricted to listening mode.
Participants can dial into the call using the following instruction.
A replay of the call will be posted on the company website http://mhtx.com.
Manhattan Scientific’s affiliate company, Imagion Biosystems Limited, formerly known as Senior Scientific, LLC, has filed a prospectus with the Australian Securities and Investment Commission and has applied to the Australian Securities Exchange for an Initial Public Offering ("IPO") to raise up to A$12 million at A$0.20 per share. You can read the Imagion offering prospectus on Imagion’s website: https://imagionbiosystems.com/investor-relations/ “go to prospectus”.
Funds raised in the IPO are expected to be used in Imagion’s efforts to move to clinical product development followed by human clinical testing. Assuming the closing of the IPO and the issuance of additional shares to Manhattan Scientifics from the conversion of a note, Manhattan Scientifics is projected to own approximately 64.1 million IBX shares equal to approximately 29.2% of Imagion.
Imagion Biosystems Limited (www.imagionbiosystems.com) is an Australian corporation with underlying business operations largely focused on research and development of the MagSense™ SPMR technology, including both the technology employed in the measuring instrument and various formulations of nanoparticles for detecting specific types of diseases
Manhattan Scientifics Inc. (www.mhtx.com) is focused on commercialization of disruptive technologies in the nano medicine space.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.